Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 1310

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7
Chunk 1310
---
 expenses 
     7,571,449  
     6,862,284  
     709,165  
     10%

    Loss from operations 
     (7,571,449) 
     (6,862,284) 
     (709,165) 
     10%

    Other expense 
     (383,889) 
     (518,509) 
     134,620  
     (26)%

    Net loss before provision for income taxes 
     (7,955,338) 
     (7,380,793) 
     (574,545) 
     8%

    Provision for income taxes 
     —  
     —  
     —  
     NA 

    Net loss 
    $(7,955,338) 
     (7,380,793) 
     (574,545) 
     8%

Operating
Expenses

Our
operating expenses consist of general and administrative expenses, research and development expenses and professional fees.

General
and Administrative Expenses

We
incurred general and administrative expenses for the years ended December 31, 2024 and 2023 of $4,110,045 and $2,738,948, respectively.
For the year ended December 31, 2024, compared to the same period in 2023, this represented an increase of $1,371,097, or 50%,
primarily as a result of increases of $495,688 in compensation expenses, an increase of $212,956 marketing expenses, an increase
of $367,723 in D&O insurance, an increase of $259,535 in IPO fees, and an increase of $137,582 in board expenses.

75 

Research
and Development Expenses

We
incurred research and development expenses for the years ended December 31, 2024 and 2023 of $1,179,436, and $2,579,418, respectively.
For the year ended December 31, 2024, compared to the same period in 2023, this represented a decrease of $1,399,982, or 54%,
with the details set forth in the table below:

    Years Ended December 31, 2024 and 2023 

    2024  
    2023  
    $ Change  
    % Change